Naltrexone/Bupropion

被引：0
|
作者：
不详
机构：
来源：
DRUGS IN R&D | 2010年 / 10卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In March 2010, Orexigen (R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave (R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32mg and bupropion SR 360 mg. The drug has been tested in four randomized, double-blind, placebo-controlled, phase III trials and the coprimary endpoints were met in each case. This review discusses the key development milestones and clinical trial program to date.
引用
收藏
页码：25 / 32
页数：8
相关论文
共 50 条
  • [31] An update on naltrexone/bupropion extended-release in the treatment of obesity
    Saunders, Katherine H.
    Igel, Leon I.
    Aronne, Louis J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (16) : 2235 - 2242
  • [32] BUPROPION/NALTREXONE FIXED-DOSE COMBINATION FOR THE TREATMENT OF OBESITY
    Halpern, B.
    Faria, A. M.
    Halpern, A.
    DRUGS OF TODAY, 2011, 47 (08) : 575 - 581
  • [33] Considerations for perioperative Contrave (naltrexone HCI/bupropion HCI) administration
    Shehebar, M.
    Khelemsky, Y.
    JOURNAL OF PAIN, 2016, 17 (04): : S83 - S83
  • [34] Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
    Greenway, Frank L.
    Dunayevich, Eduardo
    Tollefson, Gary
    Erickson, Janelle
    Guttadauria, Maria
    Fujioka, Ken
    Cowley, Michael A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (12): : 4898 - 4906
  • [35] Use of opioids with naltrexone/bupropion may cause serious AEs
    Reactions Weekly, 2024, 2020 (1) : 6 - 6
  • [36] Extended Observation of Reduced Methamphetamine Use With Bupropion and Naltrexone Treatment
    Li, Michael
    Chau, Brendon
    Belin, Thomas
    Carmody, Thomas
    Jha, Manish
    Marino, Elise
    Trivedi, Madhukar
    Shoptaw, Steve
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [37] The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
    Christou, Georgios A.
    Kiortsis, Dimitrios N.
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 14 (03): : 370 - 375
  • [38] Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
    Billes, Sonja K.
    Sinnayah, Puspha
    Cowley, Michael A.
    PHARMACOLOGICAL RESEARCH, 2014, 84 : 1 - 11
  • [39] Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
    Bello, Nicholas T.
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (07) : 549 - 552
  • [40] Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted
    Sharfstein, Joshua M.
    Psaty, Bruce M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 984 - 986
12345